NEW YORK (GenomeWeb) – Biodesix said today BlueCross BlueShield (BCBS) of Florida and Health Care Services Corporation (HCSC) have agreed to cover its Veristrat lung cancer test.
BCBS of Florida covers four million people in that state and began covering Veristrat effective March 15 of this year. HCSC, which will begin covering Veristrat on June 1, has over 15 million members in states including Illinois, Montana, New Mexico, Oklahoma, and Texas.
Veristrat, Biodesix's flagship product, is a blood-based proteomic test for assessing patient prognosis and predicting response to drug treatment in advanced NSCLC.